This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model
Cancer Immunology, Immunotherapy Open Access 16 November 2022
-
Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma
Journal of Hematology & Oncology Open Access 16 February 2022
-
Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells
Scientific Reports Open Access 05 September 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Frohn C, Hoppner M, Schlenke P, Kirchner H, Koritke P, Luhm J . Anti-myeloma activity of natural killer lymphocytes. Br J Haematol 2002; 119: 660–664.
Carbone E, Neri P, Mesuraca M, Fulciniti MT, Otsuki T, Pende D et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 2005; 105: 251–258.
Costello RT, Sivori S, Marcenaro E, Lafage-Pochitaloff M, Mozziconacci MJ, Reviron D et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 2002; 99: 3661–3667.
Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, Marcenaro E et al. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med 1998; 187: 2065–2072.
Acknowledgements
This work was supported by Groupement entreprise française lutte cancer, association pour la recherche contre le cancer, Fédération nationale des centres de lutte contre le cancer, Fondation pour la Recherche Médicale.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)
Supplementary information
Rights and permissions
About this article
Cite this article
Fauriat, C., Mallet, F., Olive, D. et al. Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma. Leukemia 20, 732–733 (2006). https://doi.org/10.1038/sj.leu.2404096
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404096
This article is cited by
-
Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model
Cancer Immunology, Immunotherapy (2023)
-
Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma
Journal of Hematology & Oncology (2022)
-
Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21
Cancer Immunology, Immunotherapy (2022)
-
The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide
Cancer Immunology, Immunotherapy (2020)
-
Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells
Scientific Reports (2017)